FDA Makes It Official With Basaglar Approval For Diabetes
This article was originally published in The Pink Sheet Daily
Eli Lilly/Boehringer Ingelheim’s insulin glargine product had already received tentative approval from FDA. The final approval clears the way for an eventual copycat version of Sanofi’s Lantus.
Register for our free email digests: